NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Divi’s Laboratories Ltd.'s Q2 FY25 earnings came above our estimates.
The company guided capex of Rs 16 billion for FY25.
We downgrade our FY25E/FY26E EPS estimates by 2.9%/3.9%, assuming lower Generic sales. We roll over to FY27 and maintain ‘Reduce’ rating with a revised target price of Rs 6,149 at 50 times FY27 P/E.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
Nalco Q2 Results Review - Broad-Based Beat Fueled By Favorable Pricing: Motilal Oswal
Nov 14, 2024
Trump 2.0: What’s In Store For Indian IT Services? Motilal Oswal's Analysis
Nov 13, 2024
Orchid Pharma Q2 Results Review - Inline Revenue, Gross Margins Come Higher: Systematix
Nov 12, 2024
Mahindra Launches Two Development Test Facilities With Rs 300-Crore Investment
Oct 23, 2024
POPULAR